Huadao (Shanghai) Biopharmaceutical
Cell immunotherapy technology developer for oncology treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Series D | |
| Total Funding | 000k | ||
Huadao (Shanghai) Biopharmaceutical is a biotechnology company established in September 2017, focusing on developing cell immunotherapy technology for oncology. The company develops Chimeric Antigen Receptor T-cell (CAR-T) technologies, providing healthcare practitioners with resources and expertise to treat conditions like acute lymphoblastic leukemia.
Headquartered in Shanghai, China, Huadao Biopharma operates in the drug discovery and pharmaceuticals industry. It aims to create China's first fully-independent CAR-T industrial transformation and production technology platform with its own intellectual properties, under the motto "Affordable cell therapy for China's middle class." The company's technology portfolio includes bacteria fermentation engineering, virus purification techniques, and T-cell acquisition and harvesting. Its drug pipeline features candidates such as HD CD19 CAR-T, HD003, HD004, and HD006.
Huadao Biopharma is a privately held, venture capital-backed company. It has raised a total of $44.7M in funding. A significant Series B funding round in August 2019 raised $14.5M, with investors including Boai Nky Pharmaceuticals and Ren Dalong. The company received a CNY 100 million injection from NKY Medical Holdings Ltd in the same year. Other investors include New Horizon Capital, Oceanpine Capital, Huzhou Industrial Group, HY Energy Group, and Zhejiang United Investment Group.
Keywords: Cell immunotherapy, CAR-T technology, oncology, drug discovery, biopharmaceutical, acute lymphoblastic leukemia, T-cell therapy, cancer treatment, China biotech, venture capital-backed, clinical trials, biologics, pharmaceuticals, life sciences, healthcare.